#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.MedicalEntity|DCT|MedicalEntity
#T_RL=webanno.custom.TLINK|TLINK|BT_webanno.custom.MedicalEntity


#Text=05.03.2023:
#Text=Kvinne 42 år med symmetriske leddsmerter MCP, PIP og håndledd bilateralt siste 4 måneder.
1-1	0-10	05.03.2023	_	_	_	_	
1-2	10-11	:	_	_	_	_	
1-3	12-18	Kvinne	_	_	_	_	
1-4	19-21	42	_	_	_	_	
1-5	22-24	år	_	_	_	_	
1-6	25-28	med	_	_	_	_	
1-7	29-40	symmetriske	OVERLAP[1]	CONDITION[1]	_	_	
1-8	41-52	leddsmerter	OVERLAP[1]	CONDITION[1]	_	_	
1-9	53-56	MCP	OVERLAP[1]	CONDITION[1]	_	_	
1-10	56-57	,	OVERLAP[1]	CONDITION[1]	_	_	
1-11	58-61	PIP	OVERLAP[1]	CONDITION[1]	_	_	
1-12	62-64	og	OVERLAP[1]	CONDITION[1]	_	_	
1-13	65-73	håndledd	OVERLAP[1]	CONDITION[1]	_	_	
1-14	74-84	bilateralt	OVERLAP[1]	CONDITION[1]	_	_	
1-15	85-90	siste	_	_	_	_	
1-16	91-92	4	_	_	_	_	
1-17	93-100	måneder	_	_	_	_	
1-18	100-101	.	_	_	_	_	

#Text=Morgenstivhet >2 timer.
2-1	102-115	Morgenstivhet	OVERLAP	CONDITION	_	_	
2-2	116-117	>	_	_	_	_	
2-3	117-118	2	_	_	_	_	
2-4	119-124	timer	_	_	_	_	
2-5	124-125	.	_	_	_	_	

#Text=RF og anti-CCP positive.
3-1	126-128	RF	OVERLAP	CONDITION	_	_	
3-2	129-131	og	_	_	_	_	
3-3	132-140	anti-CCP	BEFOREOVERLAP	CONDITION	_	_	
3-4	141-149	positive	_	_	_	_	
3-5	149-150	.	_	_	_	_	

#Text=SR 45, CRP 38.
4-1	151-153	SR	_	_	_	_	
4-2	154-156	45	_	_	_	_	
4-3	156-157	,	_	_	_	_	
4-4	158-161	CRP	_	_	_	_	
4-5	162-164	38	_	_	_	_	
4-6	164-165	.	_	_	_	_	

#Text=Starter Prednisolon 15mg og Methotrexate 15mg ukentlig.
5-1	166-173	Starter	_	_	_	_	
5-2	174-185	Prednisolon	AFTER[2]	TREATMENT[2]	_	_	
5-3	186-190	15mg	AFTER[2]	TREATMENT[2]	_	_	
5-4	191-193	og	_	_	_	_	
5-5	194-206	Methotrexate	AFTER[3]	TREATMENT[3]	OVERLAP	5-2[2_3]	
5-6	207-211	15mg	AFTER[3]	TREATMENT[3]	_	_	
5-7	212-220	ukentlig	_	_	_	_	
5-8	220-221	.	_	_	_	_	

#Text=Folsyretilskudd.
6-1	222-237	Folsyretilskudd	AFTER	TREATMENT	_	_	
6-2	237-238	.	_	_	_	_	

#Text=Henviser revmatolog.
7-1	239-247	Henviser	AFTER[4]	TREATMENT[4]	_	_	
7-2	248-258	revmatolog	AFTER[4]	TREATMENT[4]	_	_	
7-3	258-259	.	_	_	_	_	
